Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth. Click here to learn more ›

Efficacy And Safety Of The Melanocortin Agonist PL9643 In A Phase 2 Study Of Subjects With Dry Eye Disease

Scroll to Top